BioSpace News Archive

KYE Pharmaceuticals Inc. (“KYE”), a private company headquartered in Mississauga, Ontario and focused on bringing medicines that fulfill clinically significant unmet needs to the Canadian market, today announced it has submitted a New Drug Submission (NDS) to Health Canada for the regulatory review and approval of Accrufer® (ferric maltol).

AbbVie (NYSE: ABBV) and Allergan Aesthetics, an AbbVie company, today announced they will present 12 abstracts and two late-breaking presentations during the 2022 American Academy of Dermatology (AAD) Annual Meeting, March 25-29, in Boston.

NeuroSense Therapeutics Ltd. today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) to initiate a pharmacokinetic study of PrimeC in healthy adult subjects.

BRAINBox Solutions, Inc. today announced that the company, in collaboration with leading institutions, including Carilion Clinic and the Virginia Tech Carilion (VTC) School of Medicine, has been notified that they have been awarded a $3.5 million SBIR grant from the National Institute of Neurological Disorders and Stroke.

Kineta, Inc. announced today that it will present a poster on the company’s anti-CD27 agonist antibody program at the American Association for Cancer Research Annual Meeting 2022, taking place April 8-13, 2022.

Evommune, Inc., a clinical-stage biotechnology company dedicated to the development of transformative medicines for inflammatory diseases, today announced enrollment of the first participant in its Phase 1 study of EVO101 in healthy volunteers.

On the heels of Integrated DNA Technologies’ xGen™ NGS portfolio launch in December, MLL, the Munich Leukemia Laboratory, one of the leading research and diagnostic laboratories for leukemias and lymphomas, has joined the global genomics solutions provider’s Align Program.

Praxis Precision Medicines, Inc. announced that management will participate in a fireside chat at Stifel’s 4th Annual CNS Day on Tuesday, March 29, 2022 at 11:30 a.m. ET.

Taconic Biosciences has appointed Nomura Siam International Co., Ltd. (NSI) and Nomura Jimusho. Inc. (NJI) as sales agents and distributors of the rasH2 Mouse Carcinogenicity Test System in India and China, respectively.

Vivacitas Oncology, Inc. is honored to welcome, Dr. David Reardon, MD, Professor of Medicine at Harvard Medical School and Clinical Director for Dana-Farber Cancer Institute, Center for Neuro-Oncology as a new member of its top-tier Neuro-Oncology Advisory Board.